HUE064830T2 - PAR4 inhibitor kristályos alakjai - Google Patents

PAR4 inhibitor kristályos alakjai

Info

Publication number
HUE064830T2
HUE064830T2 HUE19842497A HUE19842497A HUE064830T2 HU E064830 T2 HUE064830 T2 HU E064830T2 HU E19842497 A HUE19842497 A HU E19842497A HU E19842497 A HUE19842497 A HU E19842497A HU E064830 T2 HUE064830 T2 HU E064830T2
Authority
HU
Hungary
Prior art keywords
crystalline forms
par4 inhibitor
par4
inhibitor
crystalline
Prior art date
Application number
HUE19842497A
Other languages
English (en)
Inventor
Roxana F Schlam
Nicolas Cuniere
Victoria A Mbachu
Zhongping Shi
Petinka I Vlahova
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HUE064830T2 publication Critical patent/HUE064830T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/10Succinic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HUE19842497A 2018-12-21 2019-12-20 PAR4 inhibitor kristályos alakjai HUE064830T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862783223P 2018-12-21 2018-12-21

Publications (1)

Publication Number Publication Date
HUE064830T2 true HUE064830T2 (hu) 2024-04-28

Family

ID=69187955

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19842497A HUE064830T2 (hu) 2018-12-21 2019-12-20 PAR4 inhibitor kristályos alakjai

Country Status (27)

Country Link
US (1) US20220064186A1 (hu)
EP (1) EP3898638B1 (hu)
JP (1) JP7473554B2 (hu)
KR (1) KR20210109559A (hu)
CN (1) CN113227102A (hu)
AU (1) AU2019403348A1 (hu)
BR (1) BR112021011688A2 (hu)
CA (1) CA3124100A1 (hu)
CL (1) CL2021001590A1 (hu)
CO (1) CO2021008043A2 (hu)
DK (1) DK3898638T3 (hu)
EA (1) EA202191760A1 (hu)
ES (1) ES2964404T3 (hu)
FI (1) FI3898638T3 (hu)
HR (1) HRP20231527T1 (hu)
HU (1) HUE064830T2 (hu)
IL (1) IL284222A (hu)
LT (1) LT3898638T (hu)
MX (1) MX2021007417A (hu)
PE (1) PE20211963A1 (hu)
PL (1) PL3898638T3 (hu)
PT (1) PT3898638T (hu)
RS (1) RS64900B1 (hu)
SG (1) SG11202106561RA (hu)
SI (1) SI3898638T1 (hu)
WO (1) WO2020132381A1 (hu)
ZA (1) ZA202105115B (hu)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2841437T3 (pl) 2012-04-26 2017-12-29 Bristol-Myers Squibb Company Pochodne imidazotiadiazolu i imidazopirazyny jako inhibitory receptora 4 (par4) aktywowanego proteazą do leczenia agregacji płytek

Also Published As

Publication number Publication date
CN113227102A (zh) 2021-08-06
PL3898638T3 (pl) 2023-12-04
DK3898638T3 (da) 2023-11-20
WO2020132381A1 (en) 2020-06-25
ES2964404T3 (es) 2024-04-05
EP3898638A1 (en) 2021-10-27
SI3898638T1 (sl) 2023-12-29
JP7473554B2 (ja) 2024-04-23
CA3124100A1 (en) 2020-06-25
PT3898638T (pt) 2023-11-13
RS64900B1 (sr) 2023-12-29
CL2021001590A1 (es) 2021-12-03
PE20211963A1 (es) 2021-10-04
IL284222A (en) 2021-08-31
US20220064186A1 (en) 2022-03-03
FI3898638T3 (fi) 2023-11-15
CO2021008043A2 (es) 2021-06-30
KR20210109559A (ko) 2021-09-06
BR112021011688A2 (pt) 2021-09-08
AU2019403348A1 (en) 2021-08-05
HRP20231527T1 (hr) 2024-04-26
SG11202106561RA (en) 2021-07-29
JP2022514624A (ja) 2022-02-14
ZA202105115B (en) 2024-02-28
EP3898638B1 (en) 2023-08-30
LT3898638T (lt) 2023-11-10
MX2021007417A (es) 2021-08-05
EA202191760A1 (ru) 2021-10-07

Similar Documents

Publication Publication Date Title
EP3619208C0 (en) CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND
EP4069212A4 (en) HIF-2 ALPHA INHIBITORS
ZA201903093B (en) Crystalline forms of a magl inhibitor
IL287668A (en) Crystalline forms of btk inhibitor
IL283860A (en) Crystalline forms and salt forms of a kinase inhibitor
IL289929A (en) Crystal forms of cd73 inhibitor
GB201819126D0 (en) Inhibitor compounds
ZA201904460B (en) Inhibitors of nhe-mediated antiport
IL290087A (en) inhibitory substances
IL287630A (en) Solid forms of glyt1 inhibitor
GB201914860D0 (en) Inhibitor compounds
IL277806A (en) Growth inhibitor
FI3891156T3 (fi) Mcl-1-inhibiittorin uusia kiteisiä muotoja, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
IL279953A (en) Crystal forms of LTA4H inhibitor
IL285427A (en) Crystal forms of jak2 inhibitor
IL285493A (en) Crystalline forms of rsk inhibitor
IL284222A (en) Macrocrystalline forms of the PAR4 inhibitor
GB201912411D0 (en) Crystalline forms of ivosidenib
SG11202107225SA (en) Crystalline form of a cdk inhibitor
GB201905328D0 (en) Inhibitor compounds
IL292847A (en) Crystalline forms of magl inhibitor
GB201915908D0 (en) Crystalline forms of entrectinib
IL291368A (en) Inhibits expression of methadherin
IL291456A (en) Growth retarder
GB201905318D0 (en) Inhibitor compounds